Butyrate decline as an adaptive host strategy to limit microbiota-driven tumorigenesis in later life
The age‑related drop in butyrate‑producing microbes is not merely a passive consequence of host frailty but an evolved mechanism that reduces cancer risk by curbing microbial metabolite load when immune surveillance weakens. We propose that declining butyrate lowers FFAR2/3 signaling in colonic epithelial cells, which in turn activates a transcriptional program that enhances xenobiotic detoxification and DNA repair while restraining proliferation. This shift protects against mutagenesis driven by residual bacterial activity as immunosenescence and inflammaging erode the host’s ability to control microbial overgrowth. If this hypothesis is correct, restoring butyrate levels in aged hosts should increase tumorigenesis despite improving barrier function and reducing systemic inflammation.
Testable predictions: (1) Aged mice receiving young‑donor fecal microbiota transplants or butyrate supplementation will show higher tumor burden in azoxymethane/dextran sulfate sodium‑induced colitis‑associated cancer models compared with aged controls receiving vehicle. (2) The increase in tumors will correlate with restored FFAR2/3 activation, reduced expression of detox enzymes (e.g., Nrf2 targets), and elevated epithelial proliferation markers (Ki‑67, PCNA). (3) Germ‑free aged mice colonized with a defined butyrate‑producing consortium will develop more tumors than those colonized with a butyrate‑deficient consortium, and this effect will be blocked by FFAR2/3 antagonism.
These experiments directly challenge the view that microbiome shifts in aging are purely passive dysbiosis. They also reconcile the disposable soma perspective with a specific, measurable trade‑off: the host sacrifices microbial‑derived health benefits (butyrate‑mediated colonocyte protection, anti‑inflammatory effects) to mitigate a rising oncogenic threat as intrinsic defenses decline. Confirmation would reframe longevity interventions—rather than universally boosting butyrate, we might need to temper such strategies in contexts where cancer risk outweighs the benefits of enhanced barrier integrity.